Your browser doesn't support javascript.
loading
External validation of COMPASS and BIOSCOPE prognostic scores in colorectal peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Tonello, Marco; Baratti, Dario; Sammartino, Paolo; Di Giorgio, Andrea; Robella, Manuela; Sassaroli, Cinzia; Framarini, Massimo; Valle, Mario; Macrì, Antonio; Graziosi, Luigina; Fugazzola, Paola; Lippolis, Piero Vincenzo; Gelmini, Roberta; Biacchi, Daniele; Kasamura, Shigeki; Deraco, Marcello; Cenzi, Carola; Del Bianco, Paola; Vaira, Marco; Sommariva, Antonio.
Afiliación
  • Tonello M; Unit of Surgical Oncology of the Esophagus and Digestive Tract, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
  • Baratti D; Peritoneal Surface Malignancy Unit, Dept. of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Sammartino P; Cytoreductive Surgery and HIPEC Unit, Department of Surgery "Pietro Valdoni", Sapienza University of Rome, Rome, Italy.
  • Di Giorgio A; Surgical Unit of Peritoneum and Retroperitoneum, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Robella M; Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Turin, Italy.
  • Sassaroli C; Integrated Medical Surgical Research of Peritoneal Neoplasm - Abdominal Oncology Department, "Fondazione Giovanni Pascale" IRCCS, Naples, Italy.
  • Framarini M; General and Oncologic Surgery, Morgagni - Pierantoni Hospital, AUSL Romagna, Forlì, Italy.
  • Valle M; Peritoneal Malignancies Unit, INT "Regina Elena", Rome, Italy.
  • Macrì A; Department of Human Pathology in Adulthood and Childhood "Gaetano Barresi", University of Messina, Messina, Italy.
  • Graziosi L; University of Perugia, General and Emergency Surgery Department, Santa Maria della Misericordia Hospital, Perugia, Italy.
  • Fugazzola P; General Emergency and Trauma Surgery, Bufalini Hospital, Cesena, Italy.
  • Lippolis PV; General and Peritoneal Surgery, Department of Surgery, Hospital University Pisa (AOUP), Pisa, Italy.
  • Gelmini R; General and Oncological Surgery Unit, AOU of Modena University of Modena and Reggio Emilia, Italy.
  • Biacchi D; Cytoreductive Surgery and HIPEC Unit, Department of Surgery "Pietro Valdoni", Sapienza University of Rome, Rome, Italy.
  • Kasamura S; Peritoneal Surface Malignancy Unit, Dept. of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Deraco M; Peritoneal Surface Malignancy Unit, Dept. of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Cenzi C; Unit of Surgical Oncology of the Esophagus and Digestive Tract, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
  • Del Bianco P; Clinical Research Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
  • Vaira M; Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Turin, Italy.
  • Sommariva A; Unit of Surgical Oncology of the Esophagus and Digestive Tract, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy. Electronic address: antonio.sommariva@iov.veneto.it.
Eur J Surg Oncol ; 49(3): 604-610, 2023 Mar.
Article en En | MEDLINE | ID: mdl-38432873
ABSTRACT

INTRODUCTION:

The selection of patients undergoing cytoreductive- surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) is crucial. BIOSCOPE and COMPASS are prognostic scores designed to stratify survival into four classes according to clinical and pathological features. The purpose of this study is to analyze the prognostic role of these scores using a large cohort of patients as an external reference.

METHODS:

Overall survival analysis was performed using Log-Rank and Kaplan-Meier curves for each score. The probability of survival at 12, 36, and 60 months was tested using receiver operating characteristic (ROC) curves to determine sensitivity and specificity.

RESULTS:

From the validation cohort of 437 patients, the analysis included 410 patients in the COMPASS group and 364 patients in the BIOSCOPE group (100% data completeness). We observed a different patient distribution between classes (high-risk for BIOSCOPE compared to COMPASS, p = 0.0001). Nevertheless, both COMPASS and BIOSCOPE effectively stratified overall survival (Log-Rank, p = 0.0001 in both cases), with a lack of discrimination between COMPASS classes II and III (p = n.s.). COMPASS at 12 m and BIOSCOPE at 60 m showed the best performance in terms of survival prediction (AUC of 0.82 and 0.81). The specificity of the two tests is good (median 81.3%), whereas sensibility is quite low (median 64.2%).

CONCLUSION:

Following external validation in a large population of patients with CRC-PM who are eligible for surgery, the COMPASS and BIOSCOPE scores exhibit high inter-test variability but effectively stratify cancer-related mortality risk. While the quality of the scores is similar, BIOSCOPE shows better inter-tier differentiation, suggesting that tumor molecular classification could improve test discrimination capability. More powerful stratification scores with the inclusion of novel predictors are needed.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_colon_rectum_cancers / 6_digestive_diseases / 6_other_malignant_neoplasms Asunto principal: Neoplasias Peritoneales / Neoplasias Colorrectales Límite: Humans Idioma: En Revista: Eur J Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_colon_rectum_cancers / 6_digestive_diseases / 6_other_malignant_neoplasms Asunto principal: Neoplasias Peritoneales / Neoplasias Colorrectales Límite: Humans Idioma: En Revista: Eur J Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Italia
...